Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease.
Lenti MV, Scribano ML, Biancone L, Ciccocioppo R, Pugliese D, Pastorelli L, Fiorino G, Savarino E, Caprioli FA, Ardizzone S, Fantini MC, Tontini GE, Orlando A, Sampietro GM, Sturniolo GC, Monteleone G, Vecchi M, Kohn A, Daperno M, D'Incà R, Corazza GR, Di Sabatino A. Lenti MV, et al. Among authors: fiorino g. Front Med (Lausanne). 2023 Apr 11;10:1031998. doi: 10.3389/fmed.2023.1031998. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37113615 Free PMC article. Review.
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.
Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I; SIR, SIDeMaST, and IG-IBD. Fiorino G, et al. Autoimmun Rev. 2014 Jul;13(7):751-5. doi: 10.1016/j.autrev.2014.02.004. Epub 2014 Mar 19. Autoimmun Rev. 2014. PMID: 24657898 Review.
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study".
Fries W, Viola A, Manetti N, Frankovic I, Pugliese D, Monterubbianesi R, Scalisi G, Aratari A, Cantoro L, Cappello M, Samperi L, Saibeni S, Casella G, Mocci G, Rea M, Furfaro F, Contaldo A, Magarotto A, Calella F, Manguso F, Inserra G, Privitera AC, Principi M, Castiglione F, Caprioli F, Ardizzone S, Danese S, Papi C, Bossa F, Kohn A, Armuzzi A, D'Incà R, Annese V, Alibrandi A, Bonovas S, Fiorino G; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Fries W, et al. Among authors: fiorino g. Dig Liver Dis. 2017 Jan;49(1):17-23. doi: 10.1016/j.dld.2016.09.006. Epub 2016 Sep 21. Dig Liver Dis. 2017. PMID: 27717794
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.
Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, DʼIncà R, Lionetti P, Cantoro L, Fries W, Annunziata ML, Costa F, Terpin MM, Biancone L, Cortelezzi CC, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, Andriulli A, Massari A, Lorenzon G, Ghione S, Kohn A, Ventra A, Annese V; PROSIT-BIO Cohort. Fiorino G, et al. Inflamm Bowel Dis. 2017 Feb;23(2):233-243. doi: 10.1097/MIB.0000000000000995. Inflamm Bowel Dis. 2017. PMID: 28092307
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Biancone L, et al. Dig Liver Dis. 2017 Apr;49(4):338-358. doi: 10.1016/j.dld.2017.01.141. Epub 2017 Jan 17. Dig Liver Dis. 2017. PMID: 28161290
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M. Kopylov U, et al. Among authors: fiorino g. Inflamm Bowel Dis. 2018 Oct 12;24(11):2442-2451. doi: 10.1093/ibd/izy155. Inflamm Bowel Dis. 2018. PMID: 29788318
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.
Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D'Incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, Danese S, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V; PROSIT Investigators. Armuzzi A, et al. Among authors: fiorino g. Inflamm Bowel Dis. 2019 Feb 21;25(3):568-579. doi: 10.1093/ibd/izy264. Inflamm Bowel Dis. 2019. PMID: 30137352
313 results